Vanessa Camara Fernandes

Vanessa Camara Fernandes

Auto-generated profile, based on publicly available information

Vanessa Camara Fernandes

H. Lee Moffitt Cancer Center & Research Institute 1 Department of Drug Discovery Tampa, Florida

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
VFVanessa C. Fernandes
Vanessa C. Fernandes
VGVolha Golubeva
Volha Golubeva
GPGiuliano Di Pietro
Giuliano Di Pietro
CSCara Shields
Cara Shields
KAKwabena Amankwah
Kwabena Amankwah
MCMarcelo Carvalho
Marcelo Carvalho
Genetic testing for BRCA1, a DNA repair protein, can identify carriers of pathogenic variants associated with a substantially increased risk for breast and ovarian cancers. However, an association with increased risk is unclear for a large fraction of BRCA1 variants present in the human population. Most of these variants of uncertain clinical significance lead to amino acid changes in the BRCA1 protein. Functional assays are valuable tools to assess the potential pathogenicity of these variants. Here, we systematically probed the effects of substitutions in the C terminus of BRCA1: the N- and C-terminal borders of its tandem BRCT domain, the BRCT-[N-C] linker region, and the α1 and α′1 helices in BRCT-[N] and -[C]. Using a validated transcriptional assay based on a fusion of the GAL4 DNA-binding domain to the BRCA1 C terminus (amino acids 1396–1863), we assessed the functional impact of 99 missense variants of BRCA1. We include the data obtained for these 99 missense variants in a joint analysis to generate the likelihood of pathogenicity for 347 missense variants in BRCA1 using VarCall, a Bayesian integrative statistical model. The results from this analysis increase our understanding of BRCA1 regions less tolerant to changes, identify functional borders of structural domains, and predict the likelihood of pathogenicity for 98% of all BRCA1 missense variants in this region recorded in the population. This knowledge will be critical for improving risk assessment and clinical treatment of carriers of BRCA1 variants.

10 March 2017 in Cell Cycle
Verified
Journal Article
Closed access
TNThales C. Nepomuceno
Thales C. Nepomuceno
VFVanessa C. Fernandes
Vanessa C. Fernandes
TGThiago T. Gomes
Thiago T. Gomes
RCRenato S. Carvalho
Renato S. Carvalho
GSGuilherme Suarez-Kurtz
Guilherme Suarez-Kurtz
MCMarcelo Carvalho
Marcelo Carvalho
Double strand break lesions, the most toxic type of DNA damage, are repaired primarily through 2 distinct pathways: homology-directed recombination (HR) and non-homologous end-joining (NHEJ). BRCA1 and 53BP1, 2 proteins containing the BRCT modular domain, play an important role in DNA damage response (DDR) by orchestrating the decision between HR and NHEJ, but the precise mechanisms regarding both pathways are not entirely understood. Previously, our group identified a putative interaction between BRCA1 and BARD1 (BRCA1-associated RING domain 1) and the cyclin-dependent kinase (CDK9). CDK9 is a component of the positive transcription elongation complex and has been implicated in genome integrity maintenance associated with the replication stress response. Here we show that CDK9 interacts with endogenous BRCA1 and BARD1 mediated by their RING finger and BRCT domains, and describe CDK9 ionizing radiation-induced foci (IRIF) formation and its co-localization with BRCA1 in DNA damage sites. Cells lacking CDK9 are characterized by an altered γ−H2AX foci dynamics after DNA damage, a reduced efficiency in HR but not in NHEJ repair, failure to form BRCA1 and RAD51 IRIF and increased sensitivity to genotoxic agents. These data indicate that CDK9 is a player in the DDR and is consistent with its participation in HR pathway by modulating BRCA1 response.

7 March 2023 in Clinics
Verified
Journal Article
Open access
Jamila PeriniJamila Perini
Jamila Perini
DMDaniel Machado
Daniel Machado
JCJéssica Vilarinho Cardoso
Jéssica Vilarinho Cardoso
VFVanessa Camara Fernandes
Vanessa Camara Fernandes
CSCláudio José Struchiner
Cláudio José Struchiner
GSGuilherme Suarez-Kurtz
Guilherme Suarez-Kurtz

28 September 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TNThales C. Nepomuceno
Thales C. Nepomuceno
ASAna P. P. dos Santos
Ana P. P. dos Santos
VFVanessa C. Fernandes
Vanessa C. Fernandes
AEAnna B. R. Elias
Anna B. R. Elias
TGThiago T. Gomes
Thiago T. Gomes
MCMarcelo Carvalho
Marcelo Carvalho
BRCA1 (Breast Cancer 1, early onset) is linked to breast and ovarian cancer predisposition. Still, the risks conferred by a significant portion of BRCA1 variants identified in the population remains unknown. Most of these variants of uncertain significance are missense alterations. However, the functional implications of small in-frame deletions and/or insertions (indels) are also difficult to predict. Our group has previously evaluated the functional impact of 347 missense variants using an extensively validated transcriptional activity assay. Here we show a systematic assessment of 30 naturally occurring in-frame indels located at the C-terminal region of BRCA1. We identified positions sensitive and tolerant to alterations, expanding the knowledge of structural determinants of BRCA1 function. We further designed and assessed the impact of four single codon deletions in the tBRCT linker region and six nonsense variants at the C-terminus end of BRCA1. Amino acid substitutions, deletions or insertions in the disordered region do not significantly impact activity and are not likely to constitute pathogenic alleles. On the other hand, a sizeable fraction of in-frame indels at the BRCT domain significantly impact function. We then use a Bayesian integrative statistical model to derive the probability of pathogenicity for each variant. Our data highlights the importance of assessing the impact of small in-frame indels in BRCA1 to improve risk assessment and clinical decisions for carriers.

11 June 2026
Verified
Other
Open access
YLYi Liao
Yi Liao
XLXueli Li
Xueli Li
MLMin Liu
Min Liu
VFVanessa C. Fernandes
Vanessa C. Fernandes
DDDerek Duckett
Derek Duckett
URUwe Rix
Uwe Rix
Disruption of GSH and glycolysis pathways enhances KRASG12C inhibitor efficacy. A, Scheme of mechanisms of action of BSO and glutor. B, Cell viability of H1792 (N = 3), H358 (N = 4), and HOP62 cells (N = 4) treated with BSO (500 μmol/L) or (C) glutor (50 nmol/L) alone or in combination with sotorasib (Soto; 10 μmol/L) or adagrasib (Adag; 1 μmol/L) for 96 hours. N = 3. Cell viability was measured using CellTiter-Glo luminescent cell viability assay. Data represent the mean ± SD (N = 3) and were analyzed by one-way ANOVA followed by Tukey post hoc test.

11 June 2026
Verified
Other
Open access
YLYi Liao
Yi Liao
XLXueli Li
Xueli Li
MLMin Liu
Min Liu
VFVanessa C. Fernandes
Vanessa C. Fernandes
DDDerek Duckett
Derek Duckett
URUwe Rix
Uwe Rix
GSTZ1 modulates the efficacy of KRASG12C inhibitors in KRASG12C-mutant NSCLC. A, Immunoblot analysis of GSTZ1 protein levels in noncancerous lung and KRASG12C-mutant NSCLC cell lines. B and C, Relative cell viability of H1792 and MRC-5 cells transfected with siNT or siGSTZ1 for 24 hours, followed by the treatment with sotorasib (Soto) or adagrasib (Adag) at indicated concentrations for additional 72 hours. N = 3. D, Crystal violet staining (left) and absorbance quantification (right) in H1792 cells with GSTZ1 overexpression (OE) or nontargeting control (NC) treated with Soto. GSTZ1 overexpression was confirmed by immunoblotting. N = 4. E, Viability of H1792 cells upon GSTZ1 knockout using two individual guide RNAs, sg-1and sg-2, with or without Soto treatment for 96 hours in 2D (N = 3). GSTZ1 protein levels were validated by immunoblotting. F, Cell viability of H1792 cells with NT and GSTZ1 knockout in 3D culture enabled using 96-well spheroid microplates. Soto (10 μmol/L) was incubated with spheroids for 72 hours after 48-hour spheroid formation. G, Representative brightfield images of 3D H1792 spheroids shown at scale bars of 400 μm. Cell viability was measured using 3D CellTiter-Glo luminescent cell viability assay. N = 3. Data represent the mean ± SD. Statistical significance was determined by one-way ANOVA with Tukey multiple comparisons test.